Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2009, Article ID 345324, 10 pages
http://dx.doi.org/10.1155/2009/345324
Review Article

Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction

The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA

Received 7 July 2009; Accepted 7 November 2009

Academic Editor: William Lynch

Copyright © 2009 Khanh Tran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Hellstrom, P. Ekelund, I. Milsom, and D. Mellstrom, “The prevalenc of urinary incontinence and use of incontinence aids in 85-year-old men and women,” Age and Ageing, vol. 19, no. 6, pp. 383–389, 1990. View at Google Scholar · View at Scopus
  2. J. S. Brown, D. G. Seeley, J. Fong, D. M. Black, K. E. Ensrud, and D. Grady, “Urinary incontinence in older women: who is at risk?” Obstetrics and Gynecology, vol. 87, no. 5, part 1, pp. 715–721, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. E. A. Lagace, W. Hansen, and J. M. Hickner, “Prevalence and severity of urinary incontinence in ambulatory adults: an UPRNet study,” Journal of Family Practice, vol. 36, no. 6, pp. 610–614, 1993. View at Google Scholar · View at Scopus
  4. J. G. Ouslander, R. L. Kane, and I. B. Abrass, “Urinary incontinence in elderly nursing home patients,” Journal of the American Medical Association, vol. 248, no. 10, pp. 1194–1198, 1982. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Wilson, J. S. Brown, G. P. Shin, K. O. Luc, and L. L. Subak, “Annual direct cost of urinary incontinence,” Obstetrics and Gynecology, vol. 98, no. 3, pp. 398–406, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. J. S. Brown, E. Vittinghoff, J. F. Wyman et al., “Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group,” Journal of the American Geriatrics Society, vol. 48, no. 7, pp. 721–725, 2000. View at Google Scholar · View at Scopus
  7. R. R. Dmochowski, P. K. Sand, N. R. Zinner et al., “Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence,” Urology, vol. 62, no. 2, pp. 237–242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Fantl, D. K. Newman, J. Colling et al., Urinary Incontinence in Adults: Acute and Chronic Management, Clinical Practice Guideline no. 2, Agency for Health Care Policy and Research, Rockville, Md, USA, 1996, AHCPR publication no. 96-0682.
  9. D. Thom, “Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type,” Journal of the American Geriatrics Society, vol. 46, no. 4, pp. 473–480, 1998. View at Google Scholar · View at Scopus
  10. K. L. Burgio, K. A. Matthews, and B. T. Engel, “Prevalence, incidence and correlates of urinary incontinence in healthy, middle-aged women,” Journal of Urology, vol. 146, no. 5, pp. 1255–1259, 1991. View at Google Scholar · View at Scopus
  11. T. W. Hu, T. H. Wagner, J. D. Bentkover, K. Leblanc, S. Z. Zhou, and T. Hunt, “Costs of urinary incontinence and overactive bladder in the United States: a comparative study,” Urology, vol. 63, no. 3, pp. 461–465, 2004. View at Google Scholar · View at Scopus
  12. Y. Homma, J. S. Paick, J. G. Lee, and K. Kawabe, “Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial,” BJU International, vol. 92, no. 7, pp. 741–747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. C. J. Kelleher, L. D. Cardozo, V. Khullar, and S. Salvatore, “A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance,” British Journal of Obstetrics and Gynaecology, vol. 104, no. 9, pp. 988–993, 1997. View at Google Scholar · View at Scopus
  14. H. Hashim and P. Abrams, “Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations,” Drugs, vol. 64, no. 15, pp. 1643–1656, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. K. E. Anderson, “Potential benefic of Muscarinic M3 receptor selectivity,” European Urology Supplements, vol. 1, no. 4, pp. 23–28, 2002. View at Publisher · View at Google Scholar
  16. K. Hesch, “Agents for treatment of overactive bladder: a therapeutic class review,” Baylor University Medical Center Proceedings, vol. 20, no. 3, pp. 307–314, 2007. View at Google Scholar
  17. J. R. A. Duckett, S. Hall, and A. Woodward, “A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance,” British Journal of Obstetrics and Gynaecology, vol. 105, no. 12, p. 1337, 1998. View at Google Scholar · View at Scopus
  18. C. Hampel, D. Wienhold, N. Benken, C. Eggersmann, and J. W. Thüroff, “Definition of overactive bladder and epidemiology of urinary incontinence,” Urology, vol. 50, no. 6, supplement 1, pp. 4–14, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. J. A. Couture and L. Valiquette, “Urinary incontinence,” Annals of Pharmacotherapy, vol. 34, no. 5, pp. 646–655, 2000. View at Google Scholar · View at Scopus
  20. E. A. Gormley, “Biofeedback and behavioral therapy for the management of female urinary incontinence,” Urologic Clinics of North America, vol. 29, no. 3, pp. 551–557, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. J. L. Milne and K. N. Moore, “Factors impacting self-care for urinary incontinence,” Urologic Nursing, vol. 26, no. 1, pp. 41–51, 2006. View at Google Scholar · View at Scopus
  22. D. Marcell, S. Ransel, M. Schiau, and E. G. Duffy, “Treatment option alleviates female urge incontinence,” The Nurse Practitioner, vol. 28, pp. 48–54, 2003. View at Google Scholar
  23. W. F. Stewart, J. B. Van Rooyen, G. W. Cundiff et al., “Prevalence and burden of overactive bladder in the United States,” World Journal of Urology, vol. 20, no. 6, pp. 327–336, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. J. M. Vapnek, “Urinary incontinence: screening and treatment of urinary dysfunction,” Geriatrics, vol. 56, no. 10, pp. 25–29, 2001. View at Google Scholar · View at Scopus
  25. R. M. O'Conor, M. Johannesson, S. L. Hass, and G. Kobelt-Nguyen, “Urge incontinence: quality of life and patients' valuation of symptom reduction,” PharmacoEconomics, vol. 14, no. 5, pp. 531–539, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Van Kerrebroeck, K. Kreder, U. Jonas, N. Zinner, and A. Wein, “Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder,” Urology, vol. 57, no. 3, pp. 414–421, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. M. A. Harvey, K. Baker, and G. A. Wells, “Tolterodine vs. oxybutynin in the treatment of urge UI: a meta-analysis,” American Journal of Obstetrics & Gynecology, vol. 185, pp. 56–61, 2001. View at Google Scholar
  28. H. M. Dallosso, R. J. Matthews, C. W. McGrother, M. M. K. Donaldson, and C. Shaw, “The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men,” Public Health Nutrition, vol. 7, no. 7, pp. 885–891, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. L. L. Subak, E. Whitcomb, H. Shen, J. Saxton, E. Vittinghoff, and J. S. Brown, “Weight loss: a novel and effective treatment for urinary incontinence,” Journal of Urology, vol. 174, no. 1, pp. 190–195, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. M. J. Dickson, “Nonsurgical treatment of stress urinary incontinence,” BJOG, vol. 115, no. 8, pp. 1062–1063, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. J. L. Milne, “Behavioral therapies for overactive bladder: making sense of the evidence,” Journal of Wound, Ostomy and Continence Nursing, vol. 35, no. 1, pp. 93–101, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. L. A. Arya, D. L. Myers, and N. D. Jackson, “Dietary caffeine intake and the risk for detrusor instability: a case-control study,” Obstetrics and Gynecology, vol. 96, no. 1, pp. 85–89, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Swithinbank, H. Hashim, and P. Abrams, “The effect of fluid intake on urinary symptoms in women,” Journal of Urology, vol. 174, no. 1, pp. 187–189, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. A. Shafik and I. A. Shafik, “Overactive bladder inhibition in response to pelvic floor muscle exercises,” World Journal of Urology, vol. 20, no. 6, pp. 374–377, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. K. Bø and L. C. M. Berghmans, “Nonpharmacologic treatments for overactive bladder—pelvic floor exercises,” Urology, vol. 55, no. 5, supplement 1, pp. 7–11, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. I. E. Nygaard, K. J. Kreder, M. M. Lepic, K. A. Fountain, and A. T. Rhomberg, “Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence,” American Journal of Obstetrics and Gynecology, vol. 174, no. 1, part 1, pp. 120–125, 1996. View at Publisher · View at Google Scholar · View at Scopus
  37. J. A. Fantl, J. F. Wyman, D. K. McClish et al., “Efficacy of bladder training in older women with urinary incontinence,” Journal of the American Medical Association, vol. 265, no. 5, pp. 609–613, 1991. View at Publisher · View at Google Scholar · View at Scopus
  38. L. L. Subak, C. P. Quesenberry Jr., S. F. Posner, E. Cattolica, and K. Soghikian, “The effect of behavioral therapy on urinary incontinence: a randomized controlled trial,” Obstetrics and Gynecology, vol. 100, no. 1, pp. 72–78, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. D. K. McClish, J. A. Fantl, J. F. Wyman, G. Pisani, and R. C. Bump, “Bladder training in older women with urinary incontinence: relationship between outcome and changes in urodynamic observations,” Obstetrics and Gynecology, vol. 77, no. 2, pp. 281–286, 1991. View at Google Scholar · View at Scopus
  40. D. M. Elser, J. F. Wyman, D. K. McClish et al., “The effect of bladder training, pelvic floor muscle training, or combination training on urodynamic parameters in women with urinary incontinence,” Neurourology and Urodynamics, vol. 18, no. 5, pp. 427–436, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Salvatore, M. Serati, and P. Bolis, “Tolterodine for the treatment of overactive bladder,” Expert Opinion on Pharmacotherapy, vol. 9, no. 7, pp. 1249–1255, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. K. E. Andersson, “The overactive bladder: pharmacologic basis of drug treatment,” Urology, vol. 50, no. 6A, supplement, pp. 74–79, 1997. View at Google Scholar
  43. U. Jonas, K. Höfner, H. Madersbacher, and T. H. Holmdahl, “Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group,” World Journal of Urology, vol. 15, no. 2, pp. 144–151, 1997. View at Google Scholar · View at Scopus
  44. R. Millard, J. Tuttle, K. Moore et al., “Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity,” Journal of Urology, vol. 161, no. 5, pp. 1551–1555, 1999. View at Publisher · View at Google Scholar · View at Scopus
  45. R. A. Appell, “Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis,” Urology, vol. 50, no. 6, supplement 1, pp. 90–99, 1997. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Kobelt, “Economic considerations and outcome measurement in urge incontinence,” Urology, vol. 50, no. 6, supplement 1, pp. 100–107, 1997. View at Google Scholar
  47. G. Nabi, J. D. Cody, G. Ellis, P. Herbison, and J. Hay-Smith, “Anticholinergic drugs versus placebo for overactive bladder syndrome in adults,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003781, 2006. View at Google Scholar
  48. K. Waldeck, B. Larson, and K. E. Andersson, “Comparison of oxybutynin and it's active metabolite, N-desmethyl-oxybutynin, in the human detrusor and parotid gland,” The Journal of Urology, vol. 157, pp. 1093–1097, 1997. View at Google Scholar
  49. K. M. Hughes, J. C. T. Lang, R. Lazare et al., “Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers,” Xenobiotica, vol. 22, no. 7, pp. 859–869, 1992. View at Google Scholar · View at Scopus
  50. K. M. Hughes, J. C. T. Lang, R. Lazare et al., “Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers,” Xenobiotica, vol. 22, no. 7, pp. 859–869, 1992. View at Google Scholar · View at Scopus
  51. L. Nilvebrant and B. Sparf, “Dicyclomine, benzhexol, and oxybutynine distinguish between subclasses of muscarinic binding sites,” European Journal of Pharmacology, vol. 123, no. 1, pp. 133–143, 1986. View at Google Scholar · View at Scopus
  52. M. Stöhrer, G. Mürtz, G. Kramer, F. Schnabel, E. P. Arnold, and J.-J. Wyndaele, “Propiverine compared to oxybutynin in neurogenic detrusor overactivity—results of a randomized, double-blind, multicenter clinical study,” European Urology, vol. 51, no. 1, pp. 235–242, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. M. O'Leary, J. R. Erickson, C. P. Smith, C. McDermott, J. Horton, and M. B. Chancellor, “Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury,” Journal of Spinal Cord Medicine, vol. 26, no. 2, pp. 159–162, 2003. View at Google Scholar · View at Scopus
  54. D. M. Gleason, J. Susset, C. White, D. R. Munoz, and P. K. Sand, “Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group,” Urology, vol. 54, no. 3, pp. 420–423, 1999. View at Publisher · View at Google Scholar · View at Scopus
  55. N. Bennett, M. O'Leary, A. S. Patel, M. Xavier, J. R. Erickson, and M. B. Chancellor, “Can higher doses of oxybutynin improve efficacy in neurogenic bladder?” Journal of Urology, vol. 171, no. 2, part 1, pp. 749–751, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. G. Kay, K. Kardiasmenos, and T. Crook, “Differential effects of the antimuscarinic agents tolterodine tartarate ER and oxybutynin chloride ER on recent momory in older subjects,” in Proceedings of the Annual Meeting of the International Continence Society, Christchurch, New Zealand, 2006.
  57. M. K. Kennelly, G. Lemack, J. Foote, and C. Trop, “Transdermal-oxybutynin improves continence and urodynamics in neurogenic bladder after spinal cord injury,” The Journal of Spinal Cord Medicine, vol. 30, p. 395, 2007. View at Google Scholar
  58. R. R. Dmochowski, P. K. Sand, and N. R. Zinner, “Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence,” Urology, vol. 62, pp. 237–242, 2003. View at Google Scholar
  59. S. Salvatore, M. Serati, and P. Bolis, “Tolterodine for the treatment of overactive bladder,” Expert Opinion on Pharmacotherapy, vol. 9, no. 7, pp. 1249–1255, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. L. Nilvebrant, K.-E. Andersson, P.-G. Gillberg, M. Stahl, and B. Sparf, “Tolterodine—a new bladder-selective antimuscarinic agent,” European Journal of Pharmacology, vol. 327, no. 2-3, pp. 195–207, 1997. View at Publisher · View at Google Scholar · View at Scopus
  61. M.-S. Choo, C. K. Doo, and K.-S. Lee, “Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study),” International Journal of Clinical Practice, vol. 62, no. 2, pp. 191–196, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. L. Nilvebrant, B. Hallén, and G. Larsson, “Tolterodine—a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data,” Life Sciences, vol. 60, no. 13-14, pp. 1129–1136, 1997. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Swift, A. Garely, T. Dimpfl, and C. Payne, “A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder,” International Urogynecology Journal and Pelvic Floor Dysfunction, vol. 14, no. 1, pp. 50–55, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. P. Van Kerrebroeck, K. Kreder, U. Jonas, N. Zinner, and A. Wein, “Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder,” Urology, vol. 57, no. 3, pp. 414–421, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. A. C. Diokno, R. A. Appell, P. K. Sand et al., “Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial,” Mayo Clinic Proceedings, vol. 78, no. 6, pp. 687–695, 2003. View at Google Scholar · View at Scopus
  66. R. A. Appell, P. Sand, R. Dmochowski, R. Anderson, and N. Zinner, “Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study,” Mayo Clinic Proceedings, vol. 76, no. 4, pp. 358–363, 2001. View at Google Scholar · View at Scopus
  67. D. Sussman and A. Garely, “Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET),” Current Medical Research and Opinion, vol. 18, no. 4, pp. 177–184, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. L. Rentzhog, S. L. Stanton, L. Cardozo, E. Nelson, M. Fall, and P. Abrams, “Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study,” British Journal of Urology, vol. 81, no. 1, pp. 42–48, 1998. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Abrams, R. Freeman, C. Anderstrom, and A. Mattiasson, “Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder,” British Journal of Urology, vol. 81, no. 6, pp. 801–810, 1998. View at Publisher · View at Google Scholar · View at Scopus
  70. G. Schladitz-Keil, H. Spahn, and E. Mutschler, “Determination of bioavailability of the quaternary ammonium compound trospium chloride in man from urinary excretion data,” Arzneimittel Forschung, vol. 36, pp. 984–987, 1986. View at Google Scholar
  71. D. Staskin, P. Sand, N. Zinner, and R. Dmochowski, “Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial,” Journal of Urology, vol. 178, no. 3, pp. 978–984, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. I. Füsgen and D. Hauri, “Trospium chloride: an effective option for medical treatment of bladder over-activity,” International Journal of Clinical Pharmacology and Therapeutic Toxicology, vol. 38, pp. 223–234, 2000. View at Google Scholar
  73. M. Horstmann, T. Schaefer, Y. Aguilar, A. Stenzl, and K. D. Sievert, “Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage,” Neurourology and Urodynamics, vol. 25, no. 5, pp. 441–445, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. M. Stohrere, P. Bauer, B. M. Giannetti et al., “Effect of trospium chloride on urodynamic parameter in patients with detrusor hyperreflexia due to spinal cord injuries. A multicenter placebo-controlled double-blind trial,” Urologia Internationalis, vol. 47, pp. 138–143, 1991. View at Google Scholar
  75. L. Cardozo, C. R. Chapple, P. Toozs-Hobson et al., “Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial,” BJU International, vol. 85, no. 6, pp. 659–664, 2000. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Menarini, G. Del Popolo, P. Di Benedetto et al., “Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?” International Journal of Clinical Pharmacology and Therapeutics, vol. 44, no. 12, pp. 623–632, 2006. View at Google Scholar · View at Scopus
  77. H. Madersbacher, M. Stoher, R. Richter et al., “Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia,” British Journal of Urology, vol. 75, pp. 452–456, 1995. View at Google Scholar
  78. V. A. Alabaster, “Discovery and development of selective M3 antagonists for clinical use,” Life Sciences, vol. 60, no. 13-14, pp. 1053–1060, 1997. View at Publisher · View at Google Scholar · View at Scopus
  79. C. R. Chapple, L. Cardozo, W. D. Steers, and F. E. Govier, “Solifenacin significantly improves all symptoms of overactive bladder syndrome,” International Journal of Clinical Practice, vol. 60, no. 8, pp. 959–966, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. C. R. Chapple, R. Martinez-Garcia, L. Selvaggi et al., “A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial,” European Urology, vol. 48, no. 3, pp. 464–470, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. L. Cardozo, M. Lisec, R. Millard et al., “Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder,” Journal of Urology, vol. 172, no. 5, part 1, pp. 1919–1924, 2004. View at Publisher · View at Google Scholar · View at Scopus
  82. L. Cardozo, E. Hessdorfer, R. Milani et al., “Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial,” BJU International, vol. 102, no. 9, pp. 1120–1127, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. G. Kay, T. Crook, L. Rekeda et al., “Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects,” European Urology, vol. 50, no. 2, pp. 317–326, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. M. C. Michel and J. J. M. C. H. de la Rosette, “Role of muscarinic receptor antagonists in urgency and nocturia,” BJU International, vol. 96, supplement 1, pp. 37–42, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. D. R. P. Guay, “Clinical pharmacokinetics of drugs used to treat urge incontinence,” Clinical Pharmacokinetics, vol. 42, no. 14, pp. 1243–1285, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. N. Zinner, K. C. Kobashi, U. Ebinger et al., “Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy,” International Journal of Clinical Practice, vol. 62, no. 11, pp. 1664–1674, 2008. View at Publisher · View at Google Scholar · View at PubMed
  87. “Solifenacin and darifenacin for overactive bladder,” Obstetrics & Gynecology, vol. 106, no. 2, pp. 401–402, 2005.
  88. F. Haab, L. Stewart, and P. Dwyer, “Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder,” European Urology, vol. 45, no. 4, pp. 420–429, 2004. View at Publisher · View at Google Scholar · View at PubMed
  89. C. R. Chapple, “Darifenacin is well tolerated and provide significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies,” The Journal of Urology, vol. 171, supplement, p. 130, 2004, abstract no. 487. View at Google Scholar
  90. A. Wagg, J. J. Wyndaele, and P. Sieber, “Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis,” The American Journal of Geriatric Pharmacotherapy, vol. 4, no. 1, pp. 14–24, 2006. View at Google Scholar
  91. M. B. Chancellor and F. de Miguel, “Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential,” Geriatrics, vol. 62, no. 5, pp. 15–24, 2007. View at Google Scholar
  92. C. R. Chapple and P. Abrams, “Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow,” European Urology, vol. 48, no. 1, pp. 102–109, 2005. View at Publisher · View at Google Scholar · View at PubMed
  93. S. Hill, M. Elhilali, R. J. Millard et al., “Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study,” Current Medical Research and Opinion, vol. 23, no. 11, pp. 2697–2704, 2007. View at Publisher · View at Google Scholar · View at PubMed
  94. J. Foote, K. Glavind, G. Kralidis, and J.-J. Wyndaele, “Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist,” European Urology, vol. 48, no. 3, pp. 471–477, 2005. View at Publisher · View at Google Scholar · View at PubMed
  95. K. E. Anderson, “Antimuscarinics for treatment of over-active bladder,” The Lancet Neurology, vol. 3, no. 1, pp. 46–53, 2004. View at Publisher · View at Google Scholar
  96. P. S. Goode, K. L. Burgio, J. L. Locher, M. G. Umlauf, L. K. Lloyd, and D. L. Roth, “Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women,” Journal of the American Geriatrics Society, vol. 50, no. 5, pp. 808–816, 2002. View at Publisher · View at Google Scholar
  97. A. Mattiasson, J. Blaakaer, K. Hoye, and A. J. Wein, “Simplified bladder training augments the effectiveness of tolterodine in patients with an over-active bladder,” British Journal of Urology International, vol. 91, pp. 154–160, 2003. View at Google Scholar
  98. K. L. Burgio, P. S. Goode, J. L. Locher et al., “Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial,” Journal of the American Medical Association, vol. 288, no. 18, pp. 2293–2299, 2002. View at Publisher · View at Google Scholar
  99. F. Haab, J. Corcos, P. Siami et al., “Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study,” BJU International, vol. 98, no. 5, pp. 1025–1032, 2006. View at Publisher · View at Google Scholar · View at PubMed
  100. J. F. Wyman, J. A. Fantl, D. K. McClish, and R. C. Bump, “Comparative efficacy of behavioral interventions in the management of female urinary incontinence,” American Journal of Obstetrics and Gynecology, vol. 179, no. 4, pp. 999–1007, 1998. View at Publisher · View at Google Scholar · View at Scopus
  101. C. G. Klutke, K. L. Burgio, J. F. Wyman et al., “Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication,” Journal of Urology, vol. 181, no. 6, pp. 2599–2607, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus